Search results
Showing 16 to 30 of 31 results for daratumumab
In development Reference number: GID-TA10979 Expected publication date: 11 March 2026
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
In development Reference number: GID-TA11201 Expected publication date: 11 February 2026
In development Reference number: GID-TA11162 Expected publication date: 28 July 2027
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
Awaiting development Reference number: GID-TA11815 Expected publication date: TBC
Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.
Show all sections
Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)
This guidance has been updated and replaced by NICE technology appraisal guidance 783.
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573)
This guidance has been updated and replaced by NICE technology appraisal guidance 897.
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Past technology appraisal appeals and decisions